Primary myelofibrosis: current therapeutic options
نویسندگان
چکیده
منابع مشابه
Primary myelofibrosis: current therapeutic options
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an increased risk of transformation to acute myeloid leukemia. In addition, disabling constitutional symptoms secondary to t...
متن کاملTreatment options for patients with primary myelofibrosis
Background Primary myelofibrosis (PMF) is a myeloproliferative disorder resulting in progressive bone marrow fibrosis. In some PMF patients, a mutation in the gene coding for janus-associated kinase 2 (JAK2) results in cell proliferation and evasion of apoptosis. PMF typically occurs in older patients, and is associated with poor prognosis and low survival, with death occurring secondary to car...
متن کاملEmerging therapeutic options for myelofibrosis: a Canadian perspective.
Myelofibrosis (MF) is a clonal stem cell disorder characterized by cytopenias, splenomegaly, marrow fibrosis, and systemic symptoms due to elevated inflammatory cytokines. MF is associated with decreased survival. The quality of life of patients with MF is similar to other advanced malignancies. Allogeneic hematopoietic cell transplantation is a curative treatment, but is applicable to a minori...
متن کاملCurrent therapeutic options in psoriasis
Introduction Psoriasis is a chronic skin disorder, characterized by inflammatory and hyperproliferative processes. Globally, reports on the prevalence of psoriasis reveal major differences in terms of ethnicity and climate zone, ranging between 0 and 11.8% (Jacobson et al 2011). In Europe, psoriasis affects approximately 2-3% of the population. Psoriasis onset can occur at any age, including bi...
متن کاملEsophageal Cancer: Current Options for Therapeutic Management.
BACKGROUND Esophageal cancer (EC) is the eighth most common cancer worldwide. A worldwide-established consensus on therapeutic pathways for EC is still missing. Debate exists on whether neoadjuvant and adjuvant treatment regimens improve the prognosis and which surgical approach reaches objective benefits. SUMMARY This article discusses the appropriate option of the current different curative...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Brasileira de Hematologia e Hemoterapia
سال: 2016
ISSN: 1516-8484
DOI: 10.1016/j.bjhh.2016.04.003